Your browser is no longer supported. Please, upgrade your browser.
Settings
KTOV Kitov Pharma Ltd daily Stock Chart
KTOV [NASD]
Kitov Pharma Ltd
Index- P/E- EPS (ttm)-0.30 Insider Own- Shs Outstand30.45M Perf Week-10.57%
Market Cap20.25M Forward P/E- EPS next Y- Insider Trans- Shs Float19.07M Perf Month-18.90%
Income- PEG- EPS next Q- Inst Own7.84% Short Float3.71% Perf Quarter-9.89%
Sales1.00M P/S20.25 EPS this Y- Inst Trans- Short Ratio5.25 Perf Half Y-14.92%
Book/sh0.53 P/B1.25 EPS next Y- ROA- Target Price12.00 Perf Year-41.67%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.62 - 1.72 Perf YTD-14.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.05% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low8.06% ATR0.06
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)37.88 Volatility8.80% 9.64%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume3.56 Prev Close0.67
ShortableYes LT Debt/Eq- EarningsMar 03 BMO Payout- Avg Volume134.54K Price0.67
Recom- SMA20-8.96% SMA50-11.22% SMA200-17.16% Volume106,655 Change0.75%
Nov-21-17Upgrade H.C. Wainwright Neutral → Buy $10
Feb-16-16Initiated Rodman & Renshaw Buy $10
Feb-11-20 07:00AM  Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results GlobeNewswire +6.45%
Feb-03-20 08:20AM  Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24 GlobeNewswire
Jan-24-20 08:10AM  Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors GlobeNewswire
Jan-09-20 08:35AM  Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer GlobeNewswire
Jan-08-20 07:30AM  Kitov Pharma Announces Closing of FameWave Acquisition GlobeNewswire
07:00AM  Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule GlobeNewswire
Oct-11-19 08:54AM  Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi in the U.S GlobeNewswire
Oct-02-19 08:20AM  Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board GlobeNewswire
Sep-09-19 08:30AM  Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance GlobeNewswire
Sep-03-19 08:22AM  Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference GlobeNewswire
Aug-29-19 08:30AM  Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference GlobeNewswire +21.21%
Aug-16-19 08:24AM  Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal GlobeNewswire +8.68%
Aug-14-19 08:20AM  Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority GlobeNewswire
Aug-08-19 08:20AM  Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update GlobeNewswire
Jul-12-19 05:11PM  Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements GlobeNewswire
Jun-27-19 07:30AM  Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers GlobeNewswire
May-10-19 09:20AM  Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi GlobeNewswire
May-09-19 08:30AM  Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference GlobeNewswire
May-02-19 04:45PM  Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack GlobeNewswire
Apr-12-19 08:28AM  Kitov Announces Key Milestone in FameWave Acquisition GlobeNewswire +18.18%
07:49AM  FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®) GlobeNewswire
Mar-18-19 08:20AM  Potential Milestones Coming for Kitov Pharma and Product Commercialization Plans ACCESSWIRE
Mar-14-19 02:30PM  These Four Healthcare Stocks Could Test March Highs ACCESSWIRE
09:09AM  Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company GlobeNewswire
Feb-07-19 08:06AM  Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update GlobeNewswire
Jan-21-19 08:30AM  A Biotech Play You Can't Afford To Miss ACCESSWIRE
Jan-18-19 04:30PM  Kitov Closes $6 Million Registered Direct Offering GlobeNewswire -7.64%
10:00AM  Small Caps Soaring Off of Bottoms ACCESSWIRE
09:11AM  Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY Zacks
Jan-16-19 04:26PM  Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings Zacks -42.86%
01:35PM  Kitov Announces Pricing of $6 Million Registered Direct Offering GlobeNewswire
09:26AM  4 Healthcare Stocks Seeing Gains On Wednesday (1/16/19) ACCESSWIRE
Jan-15-19 02:01PM  Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings InvestorPlace +169.23%
08:41AM  New Data on Kitovs NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect GlobeNewswire
Jan-07-19 12:25PM  4 Healthcare Stocks Making Moves On Monday (1/7/19) ACCESSWIRE -8.26%
Jan-03-19 08:35AM  4 Healthcare Stocks Gaining Speed on Thursday (1/3/19) ACCESSWIRE +44.00%
07:19AM  Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi in the U.S. with Coeptis Pharmaceuticals GlobeNewswire
Oct-15-18 08:00AM  Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of American Depository Shares and Warrants of Kitov Pharmaceuticals Holdings, Ltd. -- KTOV GlobeNewswire
Oct-11-18 08:26AM  Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer GlobeNewswire
Sep-26-18 09:40AM  Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference GlobeNewswire
Sep-18-18 12:57PM  Kitov Pharma Updates on Motions in USA Initiated by Kitov Chairman GlobeNewswire -13.00%
Aug-29-18 08:00AM  Kitov Pharma Provides Corporate Update and Reports First Half 2018 Financial Results GlobeNewswire
Jul-30-18 07:47AM  Kitov Announces Settlement of Shareholder Class Action Litigation GlobeNewswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-27-18 09:17AM  Kitov to Host Business Update Conference Call on Monday, July 2 GlobeNewswire
Jun-15-18 09:31AM  Kitov Announces Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy GlobeNewswire
Jun-01-18 08:40AM  Kitov Announces Pricing of $8,150,000 Registered Direct Offering GlobeNewswire -14.85%
08:20AM  Todays Research Reports on Stocks to Watch: Kitov Pharma and Clearside Biomedical ACCESSWIRE
May-31-18 01:45PM  FDA Approves Kitovs Consensi for Treatment of Osteoarthritis Pain and Hypertension GlobeNewswire +40.93%
May-15-18 07:00AM  Wired News Kitov Pharma Signs Consensi(TM) Commercialization Deal with Changshan Pharma in China ACCESSWIRE
May-11-18 08:30AM  Kitov Announces Consensi Commercialization Agreement for China GlobeNewswire
Apr-13-18 09:21AM  TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research PR Newswire
Mar-13-18 08:25AM  Factors of Influence in 2018, Key Indicators and Opportunity within HudBay Minerals, Delek Logistics Partners, Flex, EnPro Industries, Kitov Pharmaceuticals, and Melco Resorts & Entertainment New Research Emphasizes Economic Growth GlobeNewswire
Mar-08-18 09:33AM  TyrNovo to Present at BIO-Europe Spring® 2018 Conference PR Newswire
Mar-05-18 09:35AM  Kitov Pharmaceuticals Publishes Annual Report for 2017 and Issues CEO Letter to Shareholders PR Newswire
Dec-14-17 09:40AM  Kitov Announces Consensi as Brand Name for KIT-302 PR Newswire
Nov-01-17 09:15AM  Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package PR Newswire
Oct-26-17 02:00PM  Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function PR Newswire
Oct-06-17 08:20AM  Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock PR Newswire
Oct-04-17 07:50AM  Corporate News Blog - US FDA Accepts Kitov Pharmas Lead Drug Candidate for Full Review ACCESSWIRE
Oct-02-17 07:00AM  Kitov Announces Filing by FDA of New Drug Application for KIT-302 PR Newswire
Aug-16-17 04:35PM  Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results PR Newswire
Jul-31-17 03:20PM  Kitov Submits New Drug Application to FDA for KIT-302 PR Newswire
Jul-18-17 08:36AM  Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model PR Newswire
Jul-11-17 09:28AM  Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering PR Newswire
Jul-07-17 07:25AM  Kitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on Board Benzinga
Jun-26-17 02:37PM  Kitov Updates on KIT-302 New Drug Application PR Newswire
Jun-15-17 10:55AM  TyrNovo Ltd. to Participate in 2017 BIO International Convention PR Newswire
May-01-17 10:19AM  Kitov Pharmaceuticals Files 6-K with Update on Israeli Securities Authority Investigation PR Newswire
Apr-06-17 02:49PM  MONDAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Reminds Investors with Losses to Contact the Firm GlobeNewswire
01:58PM  Deadline Alert: GPM Reminds Investors of the April 10 Deadline in the Class Action Lawsuit Against Kitov Pharmaceutical Holdings LTD Business Wire
Apr-05-17 01:16PM  5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Reminds Investors with Losses to Contact the Firm GlobeNewswire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceuticals Holdings LTD (KTOV) and Lead Plaintiff Deadline - April 10, 2017 GlobeNewswire
Apr-04-17 03:46PM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Encourages Investors with Losses to Contact the Firm Accesswire
01:56PM  April 10 Deadline Alert: Law Offices of Howard G. Smith Reminds Kitov Pharmaceutical Holdings LTD Investors of Upcoming Lead Plaintiff Deadline Business Wire
08:15AM  Blog Coverage Kitov Received a $2 Million Filing Waiver from FDA Accesswire
Apr-03-17 09:58AM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Reminds Investors with Losses to Contact the Firm Accesswire
02:15AM  U.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing Fee PR Newswire
Apr-02-17 01:36PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Kitov Pharmaceuticals Holdings LTD to Contact the Firm Accesswire
Mar-31-17 07:12PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kitov Pharmaceuticals Holdings Ltd. of Class Action Lawsuit and Upcoming Deadline KTOV GlobeNewswire
Mar-29-17 12:02PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Encourages Investors with Losses to Contact the Firm Business Wire
10:33AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) and Lead Plaintiff Deadline - April 10, 2017
10:33AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) and Lead Plaintiff Deadline - April 10, 2017 Accesswire
Mar-28-17 07:04PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Encourages Investors with Losses to Contact the Firm Business Wire
05:45PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Kitov Pharmaceuticals Holdings LTD To Contact The Firm PR Newswire
02:10PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd. - KTOV PR Newswire
Mar-27-17 04:45PM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Encourages Investors with Losses to Contact the Firm Business Wire
08:58AM  TyrNovo, a Kitov company, to Present Preclinical Data at the American Association for Cancer Research Annual Meeting PR Newswire
Mar-24-17 07:32PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Kitov Pharmaceuticals Holdings LTD To Contact The Firm GlobeNewswire
07:01PM  Lifshitz & Miller LLP Announces Investigation of Cemtrex, Inc., Kitov Pharmaceuticals Holdings LTD, NantHealth, Inc., Omega Protein Corporation, Pearson plc, Trecora Resources, Trivago N.V. and WPP plc PR Newswire
Mar-23-17 12:56PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd., and Encourages Investors with Losses to Contact the Firm Accesswire
10:32AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) and Lead Plaintiff Deadline - April 10, 2017 Accesswire
Mar-16-17 12:15PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings Ltd. and Encourages Investors with Losses to Contact the Firm Accesswire
10:32AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) & Lead Plaintiff Deadline - April 10, 2017 Accesswire
Mar-15-17 01:01PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd., and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-14-17 05:57PM  DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Kitov Pharmaceuticals Holdings Ltd. To Contact The Firm Business Wire
Mar-13-17 05:48PM  ALERT: Rosen Law Firm Reminds Kitov Pharmaceutical Holdings Ltd. Investors of Important Deadline in Class Action - KTOV GlobeNewswire
10:50AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings Ltd. and Encourages Investors with Losses to Contact the Firm Accesswire
Mar-10-17 08:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kitov Pharmaceuticals Holdings Ltd. of Class Action Lawsuit and Upcoming Deadline - KTOV Accesswire
01:18PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd., and Encourages Investors with Losses to Contact the Firm Accesswire
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. The company operates through two segments, Pain and Hypertension; and Oncology. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is Consensi a combination of APIs celecoxib and amlodipine besylate. It is also developing NT219, a small molecule that targets two oncology-related proteins to overcome resistance to cancer drug treatment. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.